# A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

> **NCT05548556** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 51 (actual)

## Conditions studied

- Facioscapulohumeral Muscular Dystrophy (FSHD)

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO7204239

## Key facts

- **NCT ID:** NCT05548556
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-07
- **Primary completion:** 2025-05-02
- **Final completion:** 2026-10-23
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05548556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05548556, "A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05548556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*